ā¢
Sep 30, 2024
Amicus Therapeutics Q3 2024 Earnings Report
Amicus Therapeutics reported Q3 2024 results with total revenue of $141.5M, a 37% increase year-over-year and raised 2024 total revenue growth guidance to 30%-32% at CER.
Key Takeaways
Amicus Therapeutics announced strong Q3 2024 results, driven by excellent commercial performance of Galafold and Pombiliti + Opfolda, exceeding expectations and achieving non-GAAP profitability for the full year 2024.
Total revenue reached $141.5M, a 37% increase year-over-year.
Galafold revenue was $120.4M, up 20% year-over-year.
Pombiliti + Opfolda revenue reached $21.1M, up 33% from Q2 2024.
2024 total revenue growth guidance raised to 30%-32% at CER.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Forward Guidance
Amicus is focused on key strategic priorities in 2024 and is raising 2024 Total Revenue Growth Guidance to 30%-32% at CER, also reducing non-GAAP Operating Expense Guidance to $340M to $350M.